TriangleTumor-infiltrating Lymphocytes (TIL) (NCT05681780)
Tumor-infiltrating Lymphocytes (TIL) trial for Non Small Cell Lung Cancer (NCT05681780). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Some lung cancers are driven by one broken gene: EGFR, ALK, ROS1, or HER2. Targeted pills work, for a while. When they stop, immunotherapy rarely helps.
The idea: the few immune cells that did find the tumor are the right ones. Grow them into an army.
Surgeons remove a piece of tumor. In the lab, the T cells inside it are pulled out, sharpened with a signal called CD40 ligand, and multiplied into billions. After chemotherapy clears space, they return by infusion, with nivolumab to keep them switched on.
In Moffitt's earlier lung trial, tumors shrank in eleven of thirteen patients. This trial, led by Ben Creelan, asks whether it is safe in gene-driven cancers. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.